Drug
Naveglitazar
Naveglitazar: highest development phase Phase 2, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| naveglitazar NCT00065312 | Phase 2 | Diabetes Mellitus, Non-Insulin-Dependent |
Latest
No recent events.
Follow Naveglitazar on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.